APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists for Vasomotor Symptoms

Compare research editions
View pricing & licenses

Selected research

Industry Research

Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Research Report 2026

28 December 2025107 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists for Vasomotor Symptoms Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms include Astellas Pharma and Bayer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Company

Astellas Pharma

Bayer

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

Fezolinetant

Elinzanetant

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

Hospital and Clinic

Pharmacy

Other

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists for Vasomotor Symptoms.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Neurokinin Receptor Antagonists for Vasomotor Symptoms by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Manufacturers (2021-2026) Table 8. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue of Manufacturers (2021-2026) Table 9. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, Product Type & Application Table 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Astellas Pharma Company Information Table 19. Astellas Pharma Business Overview Table 20. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 22. Astellas Pharma Recent Developments Table 23. Bayer Company Information Table 24. Bayer Business Overview Table 25. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 27. Bayer Recent Developments Table 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (K Units) Table 30. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2021-2026) Table 31. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032) & (K Units) Table 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Region (2027-2032) Table 33. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2021-2026) & (US$ Million) Table 34. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2021-2026) Table 35. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2027-2032) & (US$ Million) Table 36. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2027-2032) Table 37. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 39. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 40. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (US$ Million) Table 41. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2027-2032) & (US$ Million) Table 42. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 44. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 45. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (US$ Million) Table 46. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2027-2032) & (US$ Million) Table 47. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 49. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 50. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (US$ Million) Table 51. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2027-2032) & (US$ Million) Table 52. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 53. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 54. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 55. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (US$ Million) Table 56. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2027-2032) & (US$ Million) Table 57. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 59. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2027-2032) & (K Units) Table 60. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2026) & (US$ Million) Table 61. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2027-2032) & (US$ Million) Table 62. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 63. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 64. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2026) Table 65. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2027-2032) Table 66. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2026) & (US$ Million) Table 67. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2027-2032) & (US$ Million) Table 68. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2026) Table 69. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2027-2032) Table 70. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2026) & (US$/Unit) Table 71. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2027-2032) & (US$/Unit) Table 72. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 73. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 74. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2026) Table 75. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2027-2032) Table 76. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2026) & (US$ Million) Table 77. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2027-2032) & (US$ Million) Table 78. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2026) Table 79. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2027-2032) Table 80. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2026) & (US$/Unit) Table 81. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2027-2032) & (US$/Unit) Table 82. Key Raw Materials Table 83. Raw Materials Key Suppliers Table 84. Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors List Table 85. Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers List Table 86. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends Table 87. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers Table 88. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints Table 89. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Image Figure 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size (2021-2032) & (US$ Million) Figure 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2032) & (K Units) Figure 8. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Price (US$/Unit) & (2021-2032) Figure 9. Fezolinetant Product Image Figure 10. Elinzanetant Product Image Figure 11. Hospital and Clinic Product Image Figure 12. Pharmacy Product Image Figure 13. Other Product Image Figure 14. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Neurokinin Receptor Antagonists for Vasomotor Symptoms Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region in 2025 Figure 20. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region in 2025 Figure 21. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country in 2025 Figure 22. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 23. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2032) Figure 24. United States Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country in 2025 Figure 28. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 29. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2032) Figure 30. Germany Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country in 2025 Figure 41. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2032) Figure 43. China Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country in 2025 Figure 52. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 53. South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2032) Figure 54. Brazil Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country in 2025 Figure 58. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Country (2021-2032) Figure 60. Egypt Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2032) Figure 66. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2032) Figure 67. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price (US$/Unit) by Type (2021-2032) Figure 68. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2032) Figure 69. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2032) Figure 70. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price (US$/Unit) by Application (2021-2032) Figure 71. Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Figure 72. Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges

Scope & coverage.

Types
  • Fezolinetant
  • Elinzanetant
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Astellas Pharma
  • Bayer

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size (2021-2032)
  4. 2.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2032)
  5. 2.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Average Price (2021-2032)
  6. 2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Fezolinetant
  9. 2.3.3 Elinzanetant
  10. 2.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital and Clinic
  13. 2.4.3 Pharmacy
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, Product Type & Application
  8. 3.8 Global Manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, Established Date
  9. 3.9 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Astellas Pharma
  2. 4.1.1 Astellas Pharma Company Information
  3. 4.1.2 Astellas Pharma Business Overview
  4. 4.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  6. 4.1.5 Astellas Pharma Recent Developments
  7. 4.2 Bayer
  8. 4.2.1 Bayer Company Information
  9. 4.2.2 Bayer Business Overview
  10. 4.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  12. 4.2.5 Bayer Recent Developments
5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Scenario by Region
  1. 5.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021-2032
  3. 5.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2021-2026
  4. 5.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2027-2032
  5. 5.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region: 2021-2032
  6. 5.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region: 2021-2026
  7. 5.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region: 2027-2032
  8. 5.4 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Facts & Figures by Country
  9. 5.4.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  11. 5.4.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Facts & Figures by Country
  16. 5.5.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  18. 5.5.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Facts & Figures by Country
  41. 5.7.1 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  43. 5.7.3 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032)
  2. 6.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2021-2032)
  4. 6.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2021-2032)
  5. 6.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032)
  2. 7.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2021-2032)
  4. 7.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2021-2032)
  5. 7.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Analysis
  2. 8.1.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process
  5. 8.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors
  8. 8.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers
9 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Analyzing Market Dynamics
  1. 9.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends
  2. 9.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers
  3. 9.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges
  4. 9.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst